Cerebral perfusion pressure: management protocol and clinical results

MICHAEL J. ROSNER, M.D., SHEILA D. ROSNER, R.N., M.S.N., AND ALICE H. JOHNSON, R.N., B.S.N.

Division of Neurological Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama

Early results using cerebral perfusion pressure (CPP) management techniques in persons with traumatic brain injury indicate that treatment directed at CPP is superior to traditional techniques focused on intracranial pressure (ICP) management. The authors have continued to refine management techniques directed at CPP maintenance.

One hundred fifty-eight patients with Glasgow Coma Scale (GCS) scores of 7 or lower were managed using vascular volume expansion, cerebrospinal fluid drainage via ventriculostomy, systemic vasopressors (phenylephrine or norepinephrine), and mannitol to maintain a minimum CPP of at least 70 mm Hg. Detailed outcomes and follow-up data bases were maintained. Barbiturates, hyperventilation, and hypothermia were not used.

Cerebral perfusion pressure averaged 83 ± 14 mm Hg; ICP averaged 27 ± 12 mm Hg; and mean systemic arterial blood pressure averaged 109 ± 14 mm Hg. Cerebrospinal fluid drainage averaged 100 ± 98 cc per day. Intake (6040 ± 4150 cc per day) was carefully titrated to output (5460 ± 4000 cc per day); mannitol averaged 188 ± 247 g per day. Approximately 40% of these patients required vasopressor support.

Patients requiring vasopressor support had lower GCS scores than those not requiring vasopressors (4.7 ± 1.3 vs. 5.4 ± 1.2, respectively). Patients with vasopressor support required larger amounts of mannitol, and their admission ICP was 38.7 ± 20.7 versus 17.5 ± 8.6 mm Hg for the nonvasopressor group. Although the death rate in the former group was higher, the outcome quality of the survivors was the same (Glasgow Outcome Scale scores 4.3 ± 0.9 vs. 4.5 ± 0.7). Surgical mass lesion patients had outcomes equal to those of the closed head-injury group.

Mortality ranged from 52% of patients with a GCS score of 3 to 12% of those with a GCS score of 7. Overall mortality was 29% across GCS categories. Favorable outcomes ranged from 35% of patients with a GCS score of 3 to 75% of those with a GCS score of 7. Only 2% of the patients in the series remained vegetative and if patients survived, the likelihood of their having a favorable recovery was approximately 80%. These results are significantly better than other reported series across GCS categories in comparisons of death rates, survival versus dead or vegetative, or favorable versus nonfavorable outcome classifications (Mantel-Haenszel \( \chi^2 \), \( p < 0.001 \)). Better management could have improved outcome in as many as 35% to 50% of the deaths.

KEY WORDS • cerebral perfusion pressure • intracranial pressure • traumatic brain injury • therapy

In the process of better understanding Lundberg's Plateau and B wave phenomena, a general model evolved that could be used to predict the appearance and behavior of many intracranial pressure (ICP) events and that provided a theoretical basis for the management of ICP problems in general.58 61 We have termed this model the "complex vasodilatory/vasoconstriction cascade"29 57 60 (Figs. 1-3). By stabilizing cerebral perfusion pressure (CPP) at higher levels, we found that ICP could be better controlled without cerebral ischemia.

Early results using active treatment of CPP as the primary therapeutic end point in the management of patients with traumatic brain injury (TBI)64 were encouraging. Importantly, we demonstrated that CPP could be iatrogenically elevated by inducing systemic hypertension without potentiating mortality from vasogenic edema and uncontrolled intracranial hypertension.

Subsequently, techniques have evolved from this model (Figs. 1 and 3) that form a coherent approach for managing the patient with TBI and have led to testing two closely related hypotheses: 1) management of CPP as the primary goal of therapy will yield lower mortality than that achieved with traditional, ICP-based techniques; and 2) management of CPP will result in higher Glasgow Outcome Scale (GOS)79 scores than traditional methods of therapy.

Clinical Material and Methods

Patient Population

Traumatic brain-injured patients above the age of 14 years who were admitted to the hospital with postresuscitation Glasgow Coma Scale (GCS)79 scores of 7 or below
CPP values is dynamic. These relationships change as brain injury occurs in selecting a minimum CPP (in this case above 70 mm Hg). The intra-operative increase in systemic arterial blood pressure (SABP) (J) the intracranial pressure (ICP). If the SABP component remains unchanged, CPP will further decrease and the cycle will continue until the vasodilatation is maximum or an SABP response occurs (see Fig. 2). The cascade may also be initiated at any point: for example, hypoxemia may stimulate cerebral vasodilatation and initiate the cascade. Drugs, dehydration, or ventilator settings affecting the systemic blood pressure may stimulate the cascade from the systemic side. CSF = cerebrospinal fluid; CMR-O2 = cerebral metabolic rate for oxygen.

Fig. 1. The complex vasodilatory cascade model illustrating how reducing cerebral perfusion pressure (CPP) (systemic arterial blood pressure (SABP) – intracranial pressure (ICP)) may stimulate cerebral autoregulatory vasodilatation, with an increase in cerebral blood volume (CBV) and ICP. If the SABP component remains unchanged, CPP will further decrease and the cycle will continue until the vasodilatation is maximum or an SABP response occurs (see Fig. 2). The cascade may also be initiated at any point: for example, hypoxemia may stimulate cerebral vasodilatation and initiate the cascade. Drugs, dehydration, or ventilator settings affecting the systemic blood pressure may stimulate the cascade from the systemic side. CSF = cerebrospinal fluid; CMR-O2 = cerebral metabolic rate for oxygen.

Fig. 2. Upper: Trace illustrating the reduction in cerebral perfusion pressure (CPP) stimulated by a spontaneous 15 mm Hg decrease in systemic arterial blood pressure (SABP) (1). The intracranial pressure (ICP) rose and further lowered the CPP because the SABP did not change; the process continued until the CPP increased as a result of the SABP's return to 100 mm Hg (2). This is an example (from 1 to 2) of the self-sustaining vasodilatory cascade effect. Center: The initial passive increase in ICP (termination spike T, twin horizontal arrows) before the ICP decreased, which represents the latent period of cerebral blood pressure autoregulation. Lower: The "ischemic" threshold for the A and B waves was between CPP at 60 to 70 mm Hg (large arrow), a value useful in selecting a minimum CPP (in this case above 70 mm Hg). However, the lowest ICP consistently occurred at a CPP of 85 to 90 mm Hg, which would be more appropriate as an optimal or "target" CPP as opposed to a minimal value. The selection of optimal CPP values is dynamic. These relationships change as brain injury evolves and both higher and lower optimal CPP can be identified.

and who did not follow commands within 24 hours were included in this study. Hypoxemia, traumatic asphyxia, hypotension, and multiple systemic injuries were specifically included. When mortality and morbidity were expected to be determined by the neurological injury, patients undergoing celiotomy, major orthopedic repair, and other surgical procedures were managed in the Neuroscience Intensive Care Unit (NICU).

Nearly 100 variables were collected prospectively on a daily basis.54 Inspired oxygen (FiO2), positive end-expiratory pressure (PEEP), and packed red blood cells (pRBCs) were recorded for only the last 50 patients. Hourly physiological and laboratory variables were documented as daily averages of recorded values. The physiological variables recorded hourly were the value extant "on the hour." In cases in which uncertainty existed, the value recorded on the NICU flow sheet was cross-checked against the continuously recorded data from bedside monitors (Merlin; Hewlett-Packard Co., Atlanta, GA). Data were analyzed with the assistance of commercially available software (Systat 5.52 for Windows; Systat Inc., Evanston, IL).

Monitoring of Patients

General Monitoring. All patients underwent monitoring for central venous pressure and intracranial arterial blood pressure; most patients had pulmonary artery catheters. All

and who did not follow commands within 24 hours were included in this study. Hypoxemia, traumatic asphyxia, hypotension, and multiple systemic injuries were specifically included. When mortality and morbidity were expected to be determined by the neurological injury, patients undergoing celiotomy, major orthopedic repair, and other surgical procedures were managed in the Neuroscience Intensive Care Unit (NICU).

Nearly 100 variables were collected prospectively on a daily basis.54 Inspired oxygen (FiO2), positive end-expiratory pressure (PEEP), and packed red blood cells (pRBCs) were recorded for only the last 50 patients. Hourly physiological and laboratory variables were documented as daily averages of recorded values. The physiological variables recorded hourly were the value extant "on the hour." In cases in which uncertainty existed, the value recorded on the NICU flow sheet was cross-checked against the continuously recorded data from bedside monitors (Merlin; Hewlett-Packard Co., Atlanta, GA). Data were analyzed with the assistance of commercially available software (Systat 5.52 for Windows; Systat Inc., Evanston, IL).

Monitoring of Patients

General Monitoring. All patients underwent monitoring for central venous pressure and intracranial arterial blood pressure; most patients had pulmonary artery catheters. All

M. J. Rosner, S. D. Rosner, and A. H. Johnson

FIG. 3. The "complex vasoconstriction cascade" model forms a general therapeutic model illustrating the role of high cerebral perfusion pressure (CPP) as a vasococeptor intracerebral pressure (ICP)–reducing stimulus. This model shows how vasoconstriction may be initiated at the systemic level: fluid loading red cell transfusion or the vascular volume increase brought about by mannitol is potentially effective at the systemic level. Mannitol may also stimulate the cascade primarily at the cerebral level by reducing viscosity, improving O2 delivery, and allowing vasoconstriction, which illustrates the utility of the model in understanding some of the complex effects of mannitol and other agents. The models also highlight and explain paradoxical effects such as those of the barbiturates. Pentobarbital may reduce the cerebral metabolic rate for oxygen (CMR-O2) and result in vasoconstriction with lower ICP. However, pentobarbital may significantly depress systemic arterial blood pressure (SABP) and lower CPP. The effect of the opposing stimuli may be an increase in ICP or no net ICP change. If net dehhydration following mannitol administration results in decreased SABP and/or hyperconcentration with increased viscosity, then mannitol "rebound" may well occur. CSF = cerebrospinal fluid; CBV = cerebral blood volume.
Management of CPP

transducers were referenced to the external auditory meatus with the patient nursed flat and supine.\textsuperscript{26} Table 1 lists typical admission orders.

I\textsuperscript{c}P Monitoring. Frontal ventriculostomy catheters coupled to an external transducer system with continuous oscilloscope displays of I\textsuperscript{c}P and CPP were used for I\textsuperscript{c}P monitoring. The ventriculostomy was connected to a manifoldd system (Medex Corp., Hillard, OH). Occasionally, a subdural catheter was placed as an initial or supplementary I\textsuperscript{c}P monitor at the time of craniotomy closure prior to ventriculostomy.

Ventilation of Patients. All patients were intubated. Pancuronium bromide (2–4 mg every 30–60 minutes as required) or occasionally other neuromuscular blocking agents were used to induce pharmacological paralysis; these were administered until I\textsuperscript{c}P–CPP was spontaneously maintained or required only cerebrospinal fluid (CSF) drainage. Tidal volume was initially set at 7 to 10 cc/kg (ideal weight) with a 14 to 16 breath per minute respiratory rate. A minimum of 5 cm H\textsubscript{2}O PEEP and the minimum FiO\textsubscript{2} required to obtain levels of arterial O\textsubscript{2} saturation equal to or greater than 90% were used. Minute ventilation was adjusted to maintain a targeted PaCO\textsubscript{2} of 35 mm Hg. Higher levels of PEEP were used freely to maintain arterial O\textsubscript{2} saturation at 90(+)%. Airway temperatures were maintained at 37\degree C to improve secretion management.

Continuous hyperventilation was not used as a therapeautic modality.\textsuperscript{5,51,54} Acute hyperventilation via manual "bagging" was often used for periods of acutely increased I\textsuperscript{c}P, but titrated against CPP to avoid hyperventilation-induced decreases in systemic arterial blood pressure (SABP) and CPP.

Management of Fluids and Electrolytes

Fluid Management. The goal of fluid management was to establish and maintain euvolemia to moderate hypervolemia. Pulmonary capillary wedge pressures of 12 to 15 mm Hg were used as approximate guidelines. Most fluid orders were written "intake = output + K." The "K" represents a constant to account for insensible losses; it could be increased further to allow gradual correction of dehydration or be made negative to allow gradual volume contraction.

Daily weights were obtained and used as an approximate indicator of total body water. This estimate was corrected for an expected catabolic weight loss of approximately 0.5 kg per day for each of the first 3 days and then 0.25 kg per day thereafter.\textsuperscript{2} Drug, fluid, ventilation, and hemodynamic calculations were based on "ideal" weight as estimated by the Dallas–Hall formula,\textsuperscript{89} or the actual body weight if it was lower than the expected "ideal." Patients who were well or excessively hydrated in terms of total fluid and Na\textsuperscript{+} were treated with albumin (25%), 12.5 to 25 g every 8 hours or more, to mobilize extravascular water into the vascular space. Packed red cells were frequently used as a volume expander, with absolute levels of hemoglobin and hematocrit being secondary to vascular volume as an indication for transfusion.

Electrolyte Management. Normonatremia and normokalemia were desired, but excessively positive sodium balance was avoided. Although the intravenous rate was established by output and hemodynamic parameters, fluid selection was based on spot urinary sodium and potassium concentrations obtained every 8 hours. For example, if the patient was normonatremic and excreting 60 to 80 mEq/L Na\textsuperscript{+}, then 0.45% saline (75 mEq/L) was used for replacement. During the first 72 hours after admission, glucose solutions were avoided. Lactated Ringer's solution and 0.9% NaCl were normally used for the first 24 to 48 hours after resuscitation to provide for third-space fluid losses.

Measurement of Cerebral Perfusion Pressure

Cerebral perfusion pressure was calculated as the arithmetic difference of the mean arterial pressure (MAP) and the mean I\textsuperscript{c}P with both referenced to the level of the external auditory meatus with the patient flat. Initial orders (Table 2) required a minimum CPP of 70 mm Hg. Additional orders included the active drainage of CSF whenever CPP dropped below the 70–mm Hg set point. This CSF drainage was aggressively used to maximize CPP in the least toxic fashion. If CSF drainage was insufficient to maintain CPP, vasopressors were added (Table 2). The use of vasopressors was instituted early and aggressively.

\begin{table}[h]
\centering
\begin{tabular}{|l|l|}
\hline
\textbf{Typical admission orders} & \\
\hline
1. Vital signs every hour (systemic arterial blood pressure, intracranial pressure, cerebral perfusion pressure (CPP), cerebral venous pressure, pulmonary capillary wedge pressure) & \\
2. Intake + output every hour & \\
3. Daily weights & \\
4. Cardiac profile every 8 hours (include mixed venous sampling) & \\
5. Maintain CPP at or above 70 mm Hg & \\
\text{a. Drain ventriculostomy as needed; "pop-off" at 15 mm Hg} & \\
\text{b. Titrate Levophed (4 mg/250 normal saline) to maintain CPP at or above 70 mm Hg} & \\
\text{c. If Levophed infusing, start dopamine 2 \mu g/kg per minute} & \\
\text{d. Maximum Levophed 0.2 \mu g/kg per minute unless otherwise ordered} & \\
6. Laboratory & \\
\text{a. Complete blood count with platelets} & every 8 hours \\
\text{b. Arterial blood gases} & every day \\
\text{c. International normalized ratio (anticoagulant monitoring)} & every other day \\
\text{d. Activated partial thromboplastin time} & \\
\text{e. Lactic dehydrogenase} & \\
\text{f. Serum glutamic oxaloacetic transaminase} & \\
\text{g. Alkaline phosphatase} & \\
\text{h. \gamma-Glutamyl transferase} & \\
\text{i. Carboxyhemoglobin} & \\
\text{j. Urine K} & \\
\text{k. Blood urea nitrogen} & \\
\text{l. Measurement of cerebrospinal fluid} & \\
\text{m. Use "ideal weight" for drug, fluid, and ventilator calculations} & \\
\text{n. BUN = blood urea nitrogen} & \\
\hline
\end{tabular}
\caption{Typical admission orders}
\end{table}
Pharmacological Intervention

Administration of Vasopressors. Phenylephrine was the primary vasopressor used for the first 90 to 100 patients. Orders were written to titrate this drug to maintain CPP at or above 70 mm Hg. The dose of phenylephrine was 40 to 80 mg/250 ml 0.9% NaCl but was later adjusted according to electrolyte requirements. A ceiling dose of 4.0 µg/kg per minute was ordered. Over the last 24 months norepinephrine (4 mg/250 ml 0.9% NaCl) at a maximum dosage of 0.2 to 0.4 µg/kg per minute has become the standard vasopressor. Whenever phenylephrine or norepinephrine was initiated for CPP maintenance, dopamine (400 mg/250 ml 0.9% NaCl) at 1.5 to 3.0 µg/kg per minute was begun for renal protection.

Efforts were made to minimize the dosage of vasopressors to avoid systemic toxicity. This included the active lowering of the vasopressor dose during periods of transfusion, colloid infusion, mannitol, or fluid bolus. In general, these fluids were given as rapid infusions to allow downward titration of the vasopressor.

Mannitol. When CPP declined below 70 mm Hg (and especially if the decline was secondary to an ICP increase), mannitol (0.5–1.0 g/kg over 10–20 minutes) was administered. If CPP was maintained at an acceptable level with a high but stable ICP (for example, in mm Hg: ICP 40–50, CPP 80–90), efforts were made to minimize or avoid completely the use of mannitol. If after mannitol administration CPP improved to above the desired threshold, this opportunity was used to further reduce the dose of any vasopressor.

Mannitol was used as a systemic volume expander for hemodynamic effects and isograde effects rather than to affect cerebral dehydration. Therefore, if the patient’s vascular volume status was judged to be satisfactory, the urine volume diuresed after mannitol was replaced hourly, cubic centimeter for cubic centimeter.

Barbiturate. Barbiturate-induced coma was not a part of this protocol.

Cerebral Perfusion Pressure Threshold

The threshold value for active CPP therapy was 70 mm Hg in all patients. This threshold value was increased to levels of 80 to 90+ mm Hg pending: 1) ICP values that were spontaneously lower at higher CPP levels (thus defining the new target CPP); 2) a trend toward increasing ICP in an attempt to halt this progression; and 3) the presence of cyclic CSF pressure waves (A or B waves) that were considered a priori evidence that CPP was inadequate; the “ischemic response threshold” of the wave was used as a level above which the CPP should be maintained (Fig. 2).

CPP Therapy Index. An estimate of the difficulty of CPP control was derived from a daily composite of CSF drainage (in cubic centimeters), grams of mannitol, and milligrams of phenylephrine by adding the total quantities into a unitless “index.” When norepinephrine was used, the milligram quantity was multiplied by 10 as a rough correction to keep the index comparable between patients treated with phenylephrine and norepinephrine.

Additional Factors

Temperature. Normothermia of 37°C was the goal. Active hypothermia was not a part of this protocol.

Surgery. Decompressive craniectomy, removal of normal frontal or temporal lobe for decompression, and bone flap removal were not used for ICP management.

Nutritional Support. Because of prior experience in which parenteral alimentation appeared to potentiate intracranial hypertension, patients were not alimenated until CPP and ICP were controlled for 24 hours by CSF drainage alone. Vitamin and mineral supplements were administered freely.

Patient Outcome

The GOS was used to estimate morbidity. The patient’s GOS score was assessed at 3-month intervals for the 1st

J. Neurosurg. / Volume 83 / December, 1995

M. J. Rosner, S. D. Rosner, and A. H. Johnson

TABLE 2

Basic characteristics of patient population

<table>
<thead>
<tr>
<th>Factor</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>mean age (yrs)</td>
<td>28.3±2.1</td>
<td>28.5±2.1</td>
<td>25.5±9.8</td>
<td>27.3±10.6</td>
<td>30.9±17.0</td>
<td>27.9±12.3</td>
</tr>
<tr>
<td>mean 1st ICP (mm Hg)</td>
<td>87.1±3.5</td>
<td>84.1±6.1</td>
<td>63.3±17.1</td>
<td>66.3±24.1</td>
<td>80.2±20.1</td>
<td>74.2±24.6</td>
</tr>
<tr>
<td>mean 1st CSF lactate (mmol)</td>
<td>6.3±2.1</td>
<td>2.9±0.7</td>
<td>3.9±1.7</td>
<td>3.9±1.8</td>
<td>2.6±1.0</td>
<td>4.0±2.7</td>
</tr>
<tr>
<td>cranial surgical mass lesion</td>
<td>9 7 10 10 6 42</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pupillary abnormality—one</td>
<td>7 5 7 7 7 1 27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mechanism of injury in patients</td>
<td>23</td>
<td>31</td>
<td>34</td>
<td>45</td>
<td>25</td>
<td>158</td>
</tr>
</tbody>
</table>

* GCS = Glasgow Coma Scale; ICP = intracranial pressure; CSF = cerebrospinal fluid.
Management of CPP

Table 3: Systemic injuries in 158 patients according to GCS Score

<table>
<thead>
<tr>
<th>Injury</th>
<th>GCS Scores</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3 4 5 6 7</td>
</tr>
<tr>
<td>facial</td>
<td>4 11 13 4</td>
</tr>
<tr>
<td>thoracic</td>
<td>8 13 14 6</td>
</tr>
<tr>
<td>abdominal</td>
<td>4 6 2 3</td>
</tr>
<tr>
<td>spinal fracture</td>
<td>1 2 4 3</td>
</tr>
<tr>
<td>orthopedic</td>
<td>7 12 12 10</td>
</tr>
<tr>
<td>isolated brain injury</td>
<td>13 10 10 5</td>
</tr>
<tr>
<td>total injuries</td>
<td>33 51 56 65</td>
</tr>
<tr>
<td>no. of patients</td>
<td>23 31 34 45</td>
</tr>
<tr>
<td>injuries per patient</td>
<td>1.43 1.65 1.60</td>
</tr>
</tbody>
</table>

GCS = Glasgow Coma Scale.

Results

General Results

The median postresuscitation GCS score was 5 (Table 2). The average age of these 158 patients was 27.9 ± 12 years. Most patients were injured in motor vehicle crashes (75%); assaults (7%), falls (6%), and miscellaneous mechanisms accounted for the remainder of the injuries (Table 2). Blood ethanol levels were positive in 43% and when they were averaged 137 ± 85 mg%. Systemic Injuries

Sixty-three percent of the patients in this study suffered concomitant systemic injuries (Table 3) with 8% requiring laparotomy/celiotomy (Table 4) for intraperitoneal bleeding/lesions; 37% had thoracic injuries requiring tube thoracostomy. Spinal fractures occurred in approximately 8%; long bone or pelvic fractures occurred in 31%.

Neurological Findings

Postresuscitation pupillary abnormality occurred in 46 of the patients (29%) and was distributed across GCS categories (12% unilateral, 17% bilateral postresuscitation; mannitol may have affected the frequency of this finding). The group of patients with a GCS score of 3 had more pupillary abnormality (39%) than those with a GCS score of 7 (20%). Most of the pupillary abnormality was bilateral in the severely injured (GCS score = 3) group as opposed to a single patient in the less severely injured (GCS score = 7) group.

Average CSF lactate level on admission was 4.0 ± 2.7 mmol/L and the arterial lactate averaged 3.9 ± 2.5 mmol/L. Admission ICP averaged 22.1 ± 15.8 mm Hg, but in many had been artificially reduced by mannitol given during resuscitation or by CSF loss during ventriculostomy. Twenty-seven percent of patients in this series underwent craniotomy for surgical mass lesion. Cranial computerized tomography scans were normal in only one patient; 21% of the patients had minimal abnormalities, 35% had swelling, 16% showed increased mass effect (≥5-mm shift) and/or cisternal obliteration, and 27% had intracranial surgical lesions (Tables 2 and 4).

Patient Mortality

Mortality was 29% (Table 5). The proportion of survivors making a favorable recovery by 10.5 months increased from a low of 25% among those patients with an admission GCS score of 3, to 75% among those with an admission GCS score of 7, and averaged 59% for the group. In general, if patients with GCS scores of 7 or less survived, their chances of reaching GOS scores 4 or 5 were greater than 80%. The mortality and morbidity were directly related to the admission GCS score but this relationship accounted for only 13% of the variance (GOS score = 0.50 GCS score + 0.89; p < 0.001).

In all GCS categories mortality and morbidity improved with CPP management when compared to ICP-based techniques represented in the Traumatic Coma Data Bank (TCDB) data. The Mantel–Haenszel chi square was 16.26 (p < 0.0001) for mortality. A comparison of patients whose outcomes were death or vegetative state (GOS scores 1 and 2) versus severe, moderate, and mild disability (GOS scores 3, 4, and 5) also demonstrates significant differences (Mantel–Haenszel χ² = 6.88; p = 0.009, two-tailed). The GOS scores 4 and 5 ("favorable outcome") versus GOS scores 1 to 3 ("unfavorable outcome") were also significant (Mantel–Haenszel χ² = 33.4; p < 0.0001).

Mortality of those patients suffering surgical mass lesions was 40%; the other 60% recovered to GOS scores of 4 or 5. about the same proportion as the nonsurgical patients.

Control of ICP–CPP

For the group as a whole, ICP averaged 27 ± 12 mm Hg over the first 10 days (Table 6) and 25 ± 12 mm Hg during their entire monitoring course (average 17.7 ± 13.4 days; median 15 days). The average ICP by GCS cat-
category is shown in Tables 6 and 7. The CPP and ICP were well-maintained across all GCS categories. The CPP was maintained at 83 ± 14 mm Hg for the group, but with somewhat greater difficulty as measured by the CPP index for patients with low GCS scores and for those with higher ICP values (Table 6; p < 0.001).

Figure 4 relates ICP to CPP and demonstrates the overall decrease in the ICP as the CPP increased (in mm Hg: CPP = 0.006 ICP² - 1.34 CPP + 95; p < 0.001). Elevating CPP with vasoressors did not increase ICP (Fig. 5 right).

Figure 2 demonstrates an individual’s SABP–ICP–CPP relationships. There is a latent period between a rapid increase in MAP and a decrease in ICP whether endogenously or exogenously induced. The latent period is associated with a transient increase in ICP, previously termed "termination spike," but always accompanied by an increase in CPP. More detailed data demonstrating these phenomena are extensive and will be reported separately although they have been presented in preliminary fashion6,8,12 and their physiology has been detailed10,11.

Mannitol was used freely for patients with low CPP and when administered (approximately 40% of patient days), daily doses averaged 188 g per day. The dose of phenylephrine averaged 155 mg per day (given on 30%–40% of patient days) although for the last 18 months norepinephrine (13 mg per day) has been the most commonly used vasoressor. The CSF drainage averaged 100 ± 98 cc per day.

Ninety-two percent of the patients were still actively treated by Day 5, but the progressive decline in fluids, mannitol, and vasoressor requirements of improving patients after Day 2 was manifest. After Day 5, these values were relatively constant. By Day 10, 23 patients had died and 20 were well enough to have their ventriculostomy removed. The patients who succumbed (all etiologies) had a median survival time of 10 days and the average was 20 days.

The GCS scores correlated to differences in the amount of mannitol and other forms of support required for CPP maintenance. Specifically, patients with a GCS score of 4 required twice the effort to maintain CPP than was required in patients with a GCS score of 6 (CPP index 323 ± 328 vs. 154 ± 155, respectively). The use of mannitol declined after Days 2 and 3, as did the use of blood and vasoressors. However, albumin and CSF drainage were still used and required for more prolonged periods of time. The relatively high intensity of therapy required by the "better" GCS categories was striking.

Although patients with GCS scores of 7 seemed to have higher therapeutic requirements than those with GCS scores of 6, the former group was slightly older (31 vs. 27 years) with more systemic injuries relative to isolated brain injuries (39:9) than those in the latter group (65:18) (Table 3).

Tables 8 and 9 present data comparing patients who did or did not have infection, those with motor weakness, and those who had been neurosurgically operated on. The GCS scores of 6 and 7 were associated with a higher rate of neurosurgical complications than those in the GCS score of 5 patients (72% vs. 43% and 35%, respectively) (Table 9).

TABLE 5

Comparison of patient outcomes according to admission GCS score

<table>
<thead>
<tr>
<th>GCS Score &amp; No. of Patients (%) of group</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>all patients</td>
<td>12 (52)</td>
<td>12 (40)</td>
<td>12 (35)</td>
<td>7 (16)</td>
<td>3 (12)</td>
<td>46 (29)</td>
</tr>
<tr>
<td>1 - dead</td>
<td>4 (44)</td>
<td>3 (43)</td>
<td>2 (20)</td>
<td>0 (0)</td>
<td>13 (31)</td>
<td></td>
</tr>
<tr>
<td>2 - vegetative</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>2 (33)</td>
<td>6 (14)</td>
<td></td>
</tr>
<tr>
<td>3 - severe</td>
<td>2 (11)</td>
<td>1 (14)</td>
<td>2 (20)</td>
<td>1 (17)</td>
<td>8 (19)</td>
<td></td>
</tr>
<tr>
<td>4 - moderate</td>
<td>2 (22)</td>
<td>3 (43)</td>
<td>1 (10)</td>
<td>6 (60)</td>
<td>15 (36)</td>
<td></td>
</tr>
<tr>
<td>5 - good</td>
<td>9 (100)</td>
<td>7 (100)</td>
<td>10 (100)</td>
<td>6 (100)</td>
<td>42 (100)</td>
<td></td>
</tr>
</tbody>
</table>

* GOS = Glasgow Outcome Scale;24 GCS = Glasgow Coma Scale.79
† One surviving patient from the group with a GCS score of 5 had a GOS score of better than 3 but was lost to classification.
Management of CPP

![Figure 5](image)

**FIG. 5.** Left: Scatterplot similar to that in Fig. 4 but depicting intracranial pressure (ICP) plotted against cerebral perfusion pressure (CPP) for those 93 patients who did not require vasopressor support. Note the high CPP generated by this group with the lowest ICP occurring at a CPP of 123 mm Hg. The overall relationship is described by the equation ICP = 0.003 CPP - 0.74 CPP + 61 (p < 0.001). Right: Scatterplot showing that the ICP of those patients requiring vasopressor support was much more dependent on CPP than those patients (Fig. 5 left) not requiring vasopressors. The ICP nadir occurred at CPP measuring 90 mm Hg and the relationship was described by the equation ICP = 0.01 CPP - 1.8 CPP + 114 (p < 0.001). The overall higher ICP of this group is demonstrated by the intercept of ICP and CPP at 114 mm Hg as opposed to 61 mm Hg for the nonvasopressor group.

or did not require vasopressor support on Day 1 of their admission. Those patients requiring either phenylephrine or norepinephrine for CPP support were in the minority (63 of 158; 40%); however, these patients had higher mortality rates than those not requiring vasopressors (47% vs. 18%). They also had lower admission GCS scores (4.7 vs. 6.4), their first ICP was 29 versus 18 mm Hg, and their lowest and average CPP were both much lower. If these patients survived, their outcomes were essentially equal to those not requiring early vasopressors.

**Pulmonary Data**

The PaCO₂ averaged 33 mm Hg with a goal of 35 mm Hg. The PEEP averaged 11 cm H₂O but ranged as high as 27 cm H₂O. The PaO₂ was 90 ± 16 mm Hg.

**Fluid Balance**

Intake averaged 5400 ± 3100 cc per day and output 4700 ± 3100 cc per day, providing a typically positive fluid balance (700 ± 400 cc per day). Central venous pressure was 10 mm Hg, pulmonary capillary wedge pressure was 16 mm Hg, cardiac index averaged 5.0 ± 1.0 L/min/m², and the series heart rate averaged 107 beats per minute. Some of these hemodynamic values were iatrogenically enhanced by concomitant vasopressor use.

**Causes of Death**

Most deaths occurred in persons whose GCS scores were between 3 and 5 and were directly related to TBI. Renal failure, adult respiratory distress syndrome, sepsis, and other pathologies accounted for half of the deaths. Pure intracranial hypertension that could not be controlled by CPP management accounted for seven deaths. More complex ICP problems occurred with concomitant renal failure requiring dialysis. Approximately 85% of the time, hemodialysis was associated with uncontrolled ICP and unmanageable CPP due to the systemic hemodynamic effects of renal dialysis; 12 deaths were recorded in this category. Suboptimal management explained another 13 deaths. Withdrawal of support accounted for nine deaths and miscellaneous factors for five additional deaths. Most deaths in the GCS categories of 6 and 7 were only indirectly related to brain injury.

**Discussion**

**Management of CPP**

Cerebral perfusion pressure therapy directs therapy to the pressure gradient (CPP) across the brain rather than to the isolated ICP. It requires constant assessment of SABP-ICP-CPP interactions and corresponds to the view that ICP measurement integrates brain swelling, brain edema, and tissue perfusion; if CPP is inadequate, tissue perfusion will be inadequate, and the ICP will progressively increase. Cerebral perfusion pressure therapy is not isolated from that of ICP; however, the effects of many ICP therapies are transient, potentially toxic, and better used sparingly. If CPP is stable over time, then CPP is presumably adequate and there is little reason to temporarily treat the isolated ICP.

**Physiological Basis for CPP Therapy**

Cerebral perfusion pressure is the stimulus to which the autoregulatory response of the vasculature occurs, even though the absolute arterial pressure has historically been the parameter varied in tests of autoregulation. The conclusion that cerebral autoregulation was defective after neurotrauma was often based on undefined CPP, which in some cases was less than 10 to 20 mm Hg.
TABLE 6

Physiological and therapeutic variables averaged over 10 days according to GCS score

<table>
<thead>
<tr>
<th>Variable</th>
<th>GCS 3</th>
<th>GCS 4</th>
<th>GCS 5</th>
<th>GCS 6</th>
<th>GCS 7</th>
<th>All ≤ 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>systemic arterial blood pressure (mm Hg)</td>
<td>110 ± 15</td>
<td>109 ± 16</td>
<td>108 ± 14</td>
<td>107 ± 12</td>
<td>111 ± 14</td>
<td>109 ± 14</td>
</tr>
<tr>
<td>intracranial pressure (mm Hg)</td>
<td>30 ± 12</td>
<td>31 ± 15</td>
<td>26 ± 12</td>
<td>23 ± 10</td>
<td>27 ± 12</td>
<td>27 ± 12</td>
</tr>
<tr>
<td>cerebral perfusion pressure (mm Hg)</td>
<td>82 ± 16</td>
<td>89 ± 17</td>
<td>83 ± 12</td>
<td>85 ± 13</td>
<td>85 ± 12</td>
<td>83 ± 14</td>
</tr>
<tr>
<td>weight (kg)</td>
<td>70.8 ± 14.9</td>
<td>67.7 ± 15.2</td>
<td>66.1 ± 12.1</td>
<td>68.7 ± 14.7</td>
<td>70.1 ± 12.0</td>
<td>68.2 ± 13.9</td>
</tr>
<tr>
<td>central venous pressure (mm Hg)</td>
<td>11 ± 5</td>
<td>11 ± 5</td>
<td>10 ± 4</td>
<td>9 ± 5</td>
<td>10 ± 5</td>
<td>10 ± 5</td>
</tr>
<tr>
<td>pulmonary capillary wedge pressure (mm Hg)</td>
<td>17 ± 5</td>
<td>17 ± 5</td>
<td>14 ± 4</td>
<td>16 ± 5</td>
<td>16 ± 5</td>
<td>16 ± 5</td>
</tr>
<tr>
<td>cardiac index (L/min/m²)</td>
<td>5 ± 1</td>
<td>6 ± 2</td>
<td>5 ± 1</td>
<td>5 ± 1</td>
<td>5 ± 1</td>
<td>5 ± 1</td>
</tr>
<tr>
<td>blood (cc)</td>
<td>6185 ± 4754</td>
<td>7160 ± 5448</td>
<td>6415 ± 4065</td>
<td>5111 ± 3149</td>
<td>5717 ± 3003</td>
<td>6040 ± 4150</td>
</tr>
<tr>
<td>output (cc)</td>
<td>5598 ± 112</td>
<td>6499 ± 5423</td>
<td>5734 ± 4465</td>
<td>4648 ± 2818</td>
<td>3715 ± 2630</td>
<td>4549 ± 4020</td>
</tr>
<tr>
<td>inspired oxygen (cc/day)</td>
<td>9 ± 4</td>
<td>11 ± 4</td>
<td>9 ± 4</td>
<td>11 ± 4</td>
<td>11 ± 4</td>
<td>11 ± 4</td>
</tr>
<tr>
<td>inspired end-expiratory pressure (mm Hg)</td>
<td>95 ± 26</td>
<td>96 ± 22</td>
<td>97 ± 26</td>
<td>99 ± 27</td>
<td>91 ± 26</td>
<td>96 ± 26</td>
</tr>
<tr>
<td>PaO₂ (mm Hg)</td>
<td>95 ± 26</td>
<td>96 ± 22</td>
<td>97 ± 26</td>
<td>99 ± 27</td>
<td>91 ± 26</td>
<td>96 ± 26</td>
</tr>
<tr>
<td>PaCO₂ (mm Hg)</td>
<td>33 ± 6</td>
<td>34 ± 5</td>
<td>33 ± 5</td>
<td>33 ± 5</td>
<td>34 ± 4</td>
<td>33 ± 5</td>
</tr>
<tr>
<td>hemoglobin (g/dl)</td>
<td>12 ± 1</td>
<td>12 ± 2</td>
<td>12 ± 2</td>
<td>12 ± 2</td>
<td>12 ± 1</td>
<td>12 ± 2</td>
</tr>
<tr>
<td>Na⁺ (mEq/L)</td>
<td>138 ± 7</td>
<td>138 ± 7</td>
<td>138 ± 7</td>
<td>138 ± 5</td>
<td>137 ± 5</td>
<td>138 ± 6</td>
</tr>
<tr>
<td>glucose (mm/dl)</td>
<td>160 ± 73</td>
<td>149 ± 70</td>
<td>146 ± 51</td>
<td>144 ± 54</td>
<td>137 ± 43</td>
<td>146 ± 58</td>
</tr>
<tr>
<td>creatinine (mm/dl)</td>
<td>1.6 ± 1.3</td>
<td>2.1 ± 2.7</td>
<td>1.6 ± 2.0</td>
<td>1.1 ± 0.08</td>
<td>1.4 ± 1.0</td>
<td>1.4 ± 1.7</td>
</tr>
<tr>
<td>BUN (mg/dl)</td>
<td>27 ± 27</td>
<td>33 ± 47</td>
<td>23 ± 26</td>
<td>16 ± 23</td>
<td>11 ± 22</td>
<td>13 ± 26</td>
</tr>
<tr>
<td>mannitol (g)</td>
<td>206 ± 173 (43%)</td>
<td>243 ± 213 (52%)</td>
<td>168 ± 141 (40%)</td>
<td>125 ± 136 (26%)</td>
<td>192 ± 506 (30%)</td>
<td>188 ± 247 (37%)</td>
</tr>
<tr>
<td>phenylephrine (mg)</td>
<td>117 ± 166 (40%)</td>
<td>139 ± 206 (54%)</td>
<td>127 ± 131 (48%)</td>
<td>74 ± 8 (14%)</td>
<td>118 ± 77 (25%)</td>
<td>122 ± 154 (34%)</td>
</tr>
<tr>
<td>norepinephrine (mg)</td>
<td>25 ± 18 (20%)</td>
<td>25 ± 16 (15%)</td>
<td>5 ± 4 (13%)</td>
<td>5 ± 6 (6%)</td>
<td>9 ± 6 (14%)</td>
<td>10 ± 16 (12%)</td>
</tr>
<tr>
<td>cerebral perfusion pressure index</td>
<td>285 ± 293</td>
<td>323 ± 329</td>
<td>228 ± 222</td>
<td>154 ± 155</td>
<td>208 ± 314</td>
<td>230 ± 266</td>
</tr>
</tbody>
</table>

* Values are expressed as means ± standard deviations. GCS = Glasgow Coma Scale; BUN = blood urea nitrogen.
† Only averaged for those patients actually receiving the treatment over the first 10 days. Percentage shown in parentheses indicates the percent of whole population that received treatment.

Inadequate definition of CPP has led to other disparities in the literature. As an example, the "decoupling" of the cerebral metabolic rate for oxygen and cerebral blood flow thought to occur after head injury may well be an artifact of CPP below an elevated lower limit of autoregulation. Many early studies did not report CPP or even M, J. Rosner, S. D. Rosner, and A. H. Johnson


Management of CPP

<table>
<thead>
<tr>
<th>Variable</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 5</th>
<th>Day 7</th>
<th>Day 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>no. of patients</td>
<td>158</td>
<td>156</td>
<td>153</td>
<td>146</td>
<td>131</td>
<td>115</td>
</tr>
<tr>
<td>intracranial pressure (mm Hg)</td>
<td>23 ± 12.</td>
<td>28 ± 14.</td>
<td>28 ± 15.</td>
<td>26 ± 14.</td>
<td>27 ± 11.</td>
<td>29 ± 15.</td>
</tr>
<tr>
<td>cerebral perfusion pressure (mm Hg)</td>
<td>83 ± 15.</td>
<td>83 ± 15.</td>
<td>84 ± 17.</td>
<td>84 ± 13.</td>
<td>83 ± 12.</td>
<td>81 ± 15.</td>
</tr>
<tr>
<td>weight (kg)</td>
<td>72.4 ± 15.</td>
<td>71.5 ± 14.1.</td>
<td>71.6 ± 14.6.</td>
<td>71.2 ± 15.2.</td>
<td>70.2 ± 14.6.</td>
<td>70.2 ± 15.4.</td>
</tr>
<tr>
<td>central venous pressure (mm Hg)</td>
<td>9 ± 4.</td>
<td>9 ± 4.</td>
<td>11 ± 5.</td>
<td>10 ± 5.</td>
<td>10 ± 5.</td>
<td>10 ± 4.</td>
</tr>
<tr>
<td>pulmonary capillary wedge pressure (mm Hg)</td>
<td>14 ± 4.</td>
<td>16 ± 5.</td>
<td>17 ± 5.</td>
<td>16 ± 5.</td>
<td>16 ± 5.</td>
<td>16 ± 4.</td>
</tr>
<tr>
<td>cardiac index (L/min/m²)</td>
<td>5 ± 2.</td>
<td>5 ± 1.</td>
<td>5 ± 1.</td>
<td>5 ± 1.</td>
<td>5 ± 1.</td>
<td>5 ± 1.</td>
</tr>
<tr>
<td>blood (cc)</td>
<td>1229 ± 893 (19%)</td>
<td>826 ± 597 (21%)</td>
<td>604 ± 401 (14%)</td>
<td>500 ± 206 (14%)</td>
<td>507 ± 335 (11%)</td>
<td>1006 ± 1647 (11%)</td>
</tr>
<tr>
<td>albumin (g/l)</td>
<td>102 ± 99 (75%)</td>
<td>103 ± 68 (75%)</td>
<td>98 ± 63 (69%)</td>
<td>104 ± 135 (74%)</td>
<td>101 ± 58 (79%)</td>
<td>103 ± 66 (77%)</td>
</tr>
<tr>
<td>intake (cc)</td>
<td>7969 ± 6315</td>
<td>7777 ± 5014</td>
<td>669 ± 489</td>
<td>5241 ± 2786</td>
<td>5258 ± 3933</td>
<td>5385 ± 3065</td>
</tr>
<tr>
<td>output (cc)</td>
<td>7213 ± 5532</td>
<td>7510 ± 5598</td>
<td>6525 ± 4677</td>
<td>4674 ± 2986</td>
<td>4438 ± 2658</td>
<td>498 ± 3080</td>
</tr>
<tr>
<td>inspired oxygen (mm Hg)</td>
<td>0.33 ± 0.1</td>
<td>0.27 ± 0.1</td>
<td>0.26 ± 0.1</td>
<td>0.26 ± 0.1</td>
<td>0.26 ± 0.1</td>
<td>0.26 ± 0.1</td>
</tr>
<tr>
<td>positive end-expiratory pressure (cm H2O)</td>
<td>8 ± 0.6</td>
<td>9 ± 4.</td>
<td>10 ± 3.</td>
<td>11 ± 4.</td>
<td>11 ± 4.</td>
<td>11 ± 4.</td>
</tr>
<tr>
<td>PaO2 (mm Hg)</td>
<td>126 ± 38</td>
<td>99 ± 25</td>
<td>94 ± 24</td>
<td>93 ± 20</td>
<td>91 ± 20</td>
<td>90 ± 16</td>
</tr>
<tr>
<td>PaCO2 (mm Hg)</td>
<td>32 ± 5</td>
<td>33 ± 6</td>
<td>33 ± 5</td>
<td>34 ± 5</td>
<td>34 ± 4</td>
<td>33 ± 5</td>
</tr>
<tr>
<td>hematocrit (g/dl)</td>
<td>12 ± 2</td>
<td>12 ± 2</td>
<td>12 ± 1</td>
<td>12 ± 2</td>
<td>12 ± 2</td>
<td>12 ± 2</td>
</tr>
<tr>
<td>Na+ (mEq/L)</td>
<td>139 ± 5</td>
<td>138 ± 7</td>
<td>138 ± 6</td>
<td>138 ± 6</td>
<td>138 ± 6</td>
<td>138 ± 5</td>
</tr>
<tr>
<td>glucose (mm/dl)</td>
<td>202 ± 87</td>
<td>169 ± 68</td>
<td>152 ± 56</td>
<td>128 ± 36</td>
<td>130 ± 47</td>
<td>137 ± 49</td>
</tr>
<tr>
<td>creatinine (mm/dl)</td>
<td>1.1 ± 0.3</td>
<td>1.0 ± 0.4</td>
<td>1.1 ± 0.8</td>
<td>1.6 ± 1.8</td>
<td>2.3 ± 1.7</td>
<td>1.7 ± 2.0</td>
</tr>
<tr>
<td>BUN (mm/dl)</td>
<td>11 ± 5</td>
<td>10 ± 4</td>
<td>12 ± 7</td>
<td>22 ± 22</td>
<td>32 ± 38</td>
<td>38 ± 38</td>
</tr>
<tr>
<td>mannitol (g/l)</td>
<td>244 ± 512 (46%)</td>
<td>239 ± 206 (43%)</td>
<td>197 ± 201 (37%)</td>
<td>156 ± 132 (36%)</td>
<td>163 ± 134 (38%)</td>
<td>172 ± 168 (32%)</td>
</tr>
<tr>
<td>phenylephrine (mg)</td>
<td>76 ± 73 (29%)</td>
<td>142 ± 257 (40%)</td>
<td>116 ± 121 (40%)</td>
<td>117 ± 146 (35%)</td>
<td>97 ± 127 (37%)</td>
<td>155 ± 166 (31%)</td>
</tr>
<tr>
<td>dopamine (mg)</td>
<td>7 ± 6 (16%)</td>
<td>12 ± 17 (17%)</td>
<td>19 ± 38 (12%)</td>
<td>10 ± 14 (12%)</td>
<td>7 ± 6 (6%)</td>
<td>13 ± 12 (10%)</td>
</tr>
<tr>
<td>cerebrospinal fluid</td>
<td>66 ± 92</td>
<td>89 ± 91</td>
<td>89 ± 91</td>
<td>108 ± 106</td>
<td>113 ± 99</td>
<td>107 ± 95</td>
</tr>
<tr>
<td>output (cc/day)</td>
<td>214 ± 399</td>
<td>264 ± 337</td>
<td>234 ± 293</td>
<td>222 ± 213</td>
<td>225 ± 191</td>
<td>237 ± 244</td>
</tr>
</tbody>
</table>

TABLE 7

Physiological and therapeutic variables for all patients on various days of treatment

* Values are expressed as means ± standard deviations. BUN = blood urea nitrogen.

† Only averaged for those patients actually receiving treatment on the given day. Percentage shown in parentheses indicates the percent of whole population that received treatment.

...
sion or in areas of high tissue pressure is unknown but lower than estimated by MAP–ICP. Locally reduced CPP may lead to further focal ischemic deficits and edema. The CPP may vary significantly between the supratentorial and infratentorial compartments, the spinal compartment, the parenchymal and subarachnoid spaces, and the parenchymal spaces, and where venous occlusion or obstruction may reduce the pressure gradient across the vasculature. The CPP as estimated here represents its highest possible value; the lowest is probably the more important.

The results of the use of vasopressors in this population are dramatic, but the majority of patients maintain their own CPP and do not require vasopressor support (Tables 8 and 9). Although controversial, the head flat position along with active fluid therapy has allowed the natural homeostatic and blood pressure control mechanisms to maintain endogenous CPP (Figs. 4 and 5). When needed, the dose of vasopressor has usually been quite low (< 0.2 μg/kg per minute) and served to stabilize CPP at higher levels rather than to elevate it. When CPP reached 100 to 110 mm Hg or more (Figs. 4 and 5), it was usually the patient’s endogenous catecholamines that produced the response rather than an iatrogenic effect.

This general decrease in ICP as CPP is elevated appears in Fig. 4. Tables 8 and 9 show that the death rate more than doubles in those who require vasopressor support compared to those who do not. However, the differences appear to relate to injury severity. Those requiring vasopressors had lower admission GCS scores, and a first ICP reading (before vasopressors were begun) 50% higher than the nonvasopressor group. Measures of injury severity such as mannitol use, high ICP, and others were significantly elevated in the vasopressor subgroup. Interestingly, there was no difference in SAPB. This also implies that the increase in ICP in the vasopressor group was related to the initial injury and was not potentiated by vasogenic edema secondary to elevated blood pressure.

The higher CPP of those not requiring vasopressors was not associated with progressive intracranial hypertension, higher mortality, or greater morbidity.

Study of the group requiring vasopressor support may demonstrate it to be similar to the subgroup of barbiturate responders reported by Eisenberg, et al., and combination therapy may well be ideal. Therapy that potentiates CPP by reducing ICP would be especially beneficial because the “low” CPP recorded in this group is still only 52 mm Hg, even with the use of vasopressors (nearly 20 mm Hg less than the nonvasopressor group). Most of the difference is due to the ICP, but Fig. 5 right indicates that the CPP is more dependent on CPP in this group than in the group of patients not requiring vasopressors (Fig. 5 left).

### Prognosis by CPP

McGraw and Changaris and coworkers developed an outcome model related to CPP that was averaged over 5 to 6 hours and was designated as aCPP. When aCPP was greater than 80 mm Hg, mortality was 35% to 40%. Mortality increased progressively by 20% for each decreasing 10-mm Hg epoch such that when aCPP was less than 60 mm Hg, mortality was approximately 95% or more. Morbidity and neurological deterioration were associated (p < 0.02) with decreasing CPP. However, these studies did not maintain CPP iatrogenically, which allows for the possibility that patients with severe injuries have a lower CPP but might not benefit from iatrogenic increase and maintenance of CPP; that is, low CPP may be a marker but not a cause of poor outcome after severe brain injury.

However, risks of mortality and morbidity have been improved with regimens that enhance and maintain CPP. Rosner and Daughton reported a small series of patients with GCS scores of 7 or less who had an overall mortality rate of 25% and improved mortality. Larger series have confirmed these earlier results, and noted a mortality rate of 5% in control patients in whom CPP

### TABLE 8

<table>
<thead>
<tr>
<th>Factor</th>
<th>No. of Patients</th>
<th>Age (yrs)</th>
<th>Admission GCS Score</th>
<th>Mannitol (g)</th>
<th>CSF Output (cc)</th>
<th>No. Died</th>
<th>GOS Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>no vasopressors</td>
<td>95</td>
<td>29 ± 13.1</td>
<td>5.4 ± 1.2</td>
<td>31.2 ± 64.3</td>
<td>60.4 ± 84.8</td>
<td>17</td>
<td>4.5 ± 0.7</td>
</tr>
<tr>
<td>vasopressors</td>
<td>63</td>
<td>26.7 ± 11.2</td>
<td>4.7 ± 1.3</td>
<td>23.5 ± 55.7</td>
<td>74.4 ± 101</td>
<td>30</td>
<td>4.3 ± 0.9</td>
</tr>
<tr>
<td>probability</td>
<td>0.24</td>
<td>0.001</td>
<td>0.001</td>
<td>0.35</td>
<td>0.001</td>
<td>0.13</td>
<td></td>
</tr>
</tbody>
</table>

*CPP = cerebral perfusion pressure; GCS = Glasgow Coma Scale; CSF = cerebrospinal fluid; GOS = Glasgow Outcome Scale.

### TABLE 9

<table>
<thead>
<tr>
<th>Factor</th>
<th>No. of Patients</th>
<th>Mean SABP</th>
<th>First ICP</th>
<th>Mean ICP</th>
<th>High ICP</th>
<th>First CPP</th>
<th>Mean CPP</th>
<th>Low CPP</th>
</tr>
</thead>
<tbody>
<tr>
<td>no vasopressors</td>
<td>95</td>
<td>105 ± 13.6</td>
<td>17.5 ± 8.6</td>
<td>18.1 ± 6.4</td>
<td>26.4 ± 11.1</td>
<td>92 ± 19.2</td>
<td>87.9 ± 14.0</td>
<td>73.1 ± 12.3</td>
</tr>
<tr>
<td>vasopressors</td>
<td>63</td>
<td>105 ± 11.6</td>
<td>28.7 ± 20.7</td>
<td>30.4 ± 14.7</td>
<td>45.7 ± 26.9</td>
<td>74.8 ± 21.4</td>
<td>75.9 ± 12.3</td>
<td>52.1 ± 16.2</td>
</tr>
<tr>
<td>probability</td>
<td>0.68</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

All pressures are given in mm Hg. SABP = systemic arterial blood pressure; ICP = intracranial pressure; CPP = cerebral perfusion pressure.
Management of CPP

management was used with studies of mild hypothermia; overall mortality in patients treated by maintaining a CPP of 70 mm Hg or greater is approximately 21%. The outcome improvement seen with maintenance of CPP is consistent across GCS categories although the effect is most marked at a GCS score of 3 with a substantial increase in favorable outcomes.

The improvement in quantity and quality of survival is not likely to be due merely to the avoidance of in-hospital hypotension. In part the level of blood pressure called hypotensive in many studies is a systolic blood pressure of less than 90 mm Hg. Although hypotension to this degree may occur, the studies of Changaris and coworkers and McGraw suggest improvement in outcome is related to higher CPP levels.

Traumatic Coma Data Bank and Other Studies

A potential criticism of these results relates to the basic assumption that the patient population under discussion is essentially equivalent to the patients of the TCDB. However, the University of Alabama Hospital is a major regional tertiary care facility, serves a combination of urban and rural referral hospitals as do most of the TCDB centers, and has an active organ transplantation program that draws potential donors. Moreover, no significant differences in age, sex, or mechanism of injury between patients from either series have been identified.

Pupillary abnormality occurred more frequently in the TCDB patients (37%) than in those in this series (29%). It is difficult to know the source of this difference but the TCDB rate of pupillary abnormality includes patients with GCS scores of 8, 9, and above and does not allow for separation of groups such as those with GCS scores less than or equal to 7, which comprise this series. Although one expects fewer pupillary abnormalities in the groups with higher GCS scores (≥8), some will occur and contribute to the 8% difference. Postresuscitation pupillary abnormality in the current series may also have been reduced by early use of mannitol during resuscitation, a practice encouraged by these authors.

Another potential difference that might account for the differences in outcome is the rate of surgical mass lesion: 27% in the current series versus 37% in the TCDB study. As in the case of pupillary abnormality, the TCDB figure includes patients with GCS scores of 8 or higher, but does not allow extraction by GCS score. Some of the 10% difference can be explained in this fashion and some by the degree of cerebral consultation that different centers may tolerate before assigning the patient to surgery. Another potential explanation is that patients in this series did not undergo lobectomy for treatment of intracranial hypertension. Last, the lower percentage of the current series (27%) undergoing surgery does not account for the overall improvement in outcome because the GOS scores of CPP-treated patients with mass lesions were 4 or 5 (favorable) in 60% of the cases; that is, the patients with surgical mass lesions did not contribute to, or detract from, the good outcomes of the series and do not account for the overall difference between this group and that of the TCDB.

The 1991 TCDB results are generally representative of the overall outcome reported by most studies published within the “modern” era of TBI treatment and are used for detailed comparison because they allow comparison by GCS score. For example, Jennett reported mortality rates ranging from 46% to 54% for patients treated during 1970 and 1977 from three centers. The overall favorable outcome of 1100 TBI patients reported in 1982 by Gennarelli, et al., was 42% with an accompanying 41% mortality rate. This series included patients with GCS scores of 8 who had been in coma less than 24 hours. In 1987 Alberico and colleagues reported a 1-year favorable outcome of approximately 44% in adults (≥20 years of age) versus 69% of children/adolescents (<20 years of age). However, overall mortality was still 42%, with those 20 years of age or older having a 50% mortality rate versus a 25% mortality rate in the younger patients. Another large study by Colohan and coworkers in 1989 compared the outcomes in New Delhi, India, with those at the University of Virginia and found only a small difference in results in patients localizing to pain. The general mortality ranged from 80% to 89% among those with GCS scores of 3, to 40% to 55% for patients with GCS scores of 4 to 6. These data are quite close to those reported in the TCDB.

The striking feature of results reported from 1970 to the present with ICP-based techniques is how little impact, if any, their application seems to have made on outcome: an observation used by some to conclude that ICP monitoring is not useful. However, management in TCDB centers changed over time with a tremendous reduction in the number of deaths in persons “talked and died” from 50% to 26%. Although the current series has a similar group of patients, the number is too small for comparison. Other sources for improvement in outcome beyond the very early evacuation of mass lesions lie in improved prehospital care.

Summary and Conclusions

Summary of the Series

Cerebral ischemia dominates TBI as the single most important event determining outcome. The primary role of CPP maintenance is the preservation of CBF; regardless of vasospasm, abnormalities of autoregulation, or vessel obstruction, it is this pressure gradient (CPP) that will be most important in maintaining CBF and the most amenable to manipulation by the physician.

The improvement in quality of survival also contrasts directly with the view that induced hypertension will potentiate cerebral edema and dysautoregulation. Direct evidence showing that “pressure passive” ICP–SABP responses are limited to CPP levels, in which cerebral autoregulation has not yet become effective (that is, CPP too low), has been presented. Figures 4 and 5 summarize the general relationship between CPP and ICP over patients and time. These data do not support the concept of cerebral edema being potentiated by systemic hypertension and high CPP.

Cerebral perfusion pressure is a physiological parameter intimately linked with ICP and SABP; and of the three, it is the greatest determinant of cerebral hemodynamic responses and effects. Cerebral perfusion pressure can be manipulated safely to reduce both mortality and morbidity.
ty after TBI: management of CPP is a viable and effective end point in the treatment of TBI.

Conclusions

Cerebral perfusion pressure management can serve as the primary goal in the treatment of traumatic intracranial hypertension with substantially improved mortality and morbidity following TBI. The minimum level of CPP in this instance is greater than 70 mm Hg and frequently higher, defined by individual circumstances that may occasionally require a level of 100 mm Hg or more, but average 85 mm Hg. Systemic hypertension and iatrogenic maintenance of CPP do not potentiate or worsen intracranial hypertension.

Acknowledgments

The authors wish to thank the neurosurgical faculty for their cooperation and support in the collection of this data. We sincerely thank Mrs. Debbie Mielke for the preparation of this manuscript. Special thanks go to the University of Alabama at Birmingham's Injury Control Research Center's Epidemiology and Surveillance Work Group for review of the manuscript data, and statistical methods.

Dedication

This manuscript is dedicated to the memory of M. Stephen Mahaley, M.D., Ph.D. (1932-1992). Dr. Mahaley's support, encouragement, and enthusiasm for this project made possible the development of what once were difficult concepts. That support, both personal and professional, represents a debt that this author (M.J.R.) can never adequately repay.

References


M. J. Rosner, S. D. Rosner, and A. H. Johnson

32. Langfitt TW, Weinstein JD, Kassell NF: Cerebral vasomotor...
Management of CPP


McGraw CP: A cerebral perfusion pressure greater than 80 mm Hg is more beneficial, in Hoff JT, Betz AL (eds): Intracranial Pressure VII. Berlin: Springer-Verlag, 1989, pp 839-841


Seelig JM, Becker DP, Miller JD, et al: Traumatic acute subdural hematoma. Major mortality reduction in comatose pa-


Manuscript received August 11, 1994. Accepted in final form May 18, 1995.

This study was supported, in part, by Grant No: R49/CCR40364 from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention—National Center for Injury Prevention and Control to the University of Alabama at Birmingham, Injury Control Research Center.

Address reprint requests to: Michael J. Rosner, M.D., Division of Neurological Surgery, 516 Medical Education Building, University of Alabama at Birmingham, 1813 Sixth Avenue South, Birmingham, Alabama 35294–3295.